Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ruiz, Ximena D ^a   Mlakar, Logan R ^a   Yamaguchi, Yukie ^a   Su, Yunyun ^a   Larregina, Adriana T ^a   Pilewski, Joseph M ^a   Feghali Bostwick, Carol A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SYNDECAN 2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FIBROSING ALVEOLITIS; GENE; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG PARENCHYMA; MKNK2 GENE; ORGAN CULTURE; PROTEIN EXPRESSION; PROTEIN TARGETING; SDC2 GENE; SKIN; SYSTEMIC SCLEROSIS; TISSUE LEVEL;

CELLS, CULTURED; ENZYME ACTIVATION; FIBROSIS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SKIN; SYNDECAN-2; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865037906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043049     Document Type: Article

References (44)

1. Blobe GC, Schiemann WP, Lodish HF, ((2000)) Role of transforming growth factor beta in human disease. N Engl J Med 342:: 1350--8.
2. Leask A, Abraham DJ, ((2004)) TGF-beta signaling and the fibrotic response. FASEB J 18:: 816--27.
3. Martin JL, Baxter RC, ((1991)) Transforming growth factor-beta stimulates production of insulin-like growth factor-binding protein-3 by human skin fibroblasts. Endocrinology 128:: 1425--1433.
4. Oh Y, Muller HL, Ng L, Rosenfeld RG, ((1995)) Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270:: 13589--13592.
5. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG, ((1996)) Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56:: 1545--1550.
6. Hwa V, Oh Y, Rosenfeld RG, ((1997)) Insulin-like growth factor binding protein-3 and-5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 6:: 235--242.
7. Rajah R, Valentinis B, Cohen P, ((1997)) Insulin-like growth factor IGF-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:: 12181--12188.
8. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA, ((2005)) Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 166:: 399--407.
9. Kuemmerle JF, Murthy KS, Bowers JG, ((2004)) IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 287:: G795--G802.
10. Lee KW, Liu B, Ma L, Li H, Bang P, et al. ((2004)) Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 279:: 469--476.
11. Aston C, Jagirdar J, Lee TC, Hur T, Hintz RL, et al. ((1995)) Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 151:: 1597--1603.
12. Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA, ((2008)) Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J 2:: 17--22.
13. Yasuoka H, Jukic DM, Zhou Z, Choi AM, Feghali-Bostwick CA, ((2006)) Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis. Arthritis Rheum 54:: 3001--3010.
14. Venkatesan N, Roughley PJ, Ludwig MS, ((2002)) Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta1 and interferon-gamma. Am J Physiol Lung Cell Mol Physiol 283:: L806--L814.
15. Sebestyén A, Gallai M, Knittel T, Ambrust T, Ramadori G, et al. ((2000)) Cytokine regulation of syndecan expression in cells of liver origin. Cytokine 12:: 1557--1560.
16. Worapamorn W, Haase HR, Li H, Bartold PM, ((2001)) Growth factors and cytokines modulate gene expression of cell-surface proteoglycans I human periodontal ligament cells. J Cell Physiol 186:: 448--456.
17. Worapamorn W, Tam SP, Li H, Haase HR, Bartold PM, ((2002)) Cytokine regulation of syndecan-1 and-2 gene expression in human periodontal fibroblasts and osteoblasts. J Periodontal Res 37:: 273--278.
18. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA, ((1997)) Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mknk2. EMBO J 168:: 1909--20.
19. Bernfield M, Kokenyesi M, Kato M, Hinkes MT, Spring J, et al. ((1992)) Biology of the syndecans: a family of transmembrane heparin sulfate proteoglycans. Annu Rev Cell Biol 8:: 365--393.
20. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, et al. ((1999)) Functions of cell surface heparan sulphate proteoglycans. Annu Rev Biochem 68:: 729--777.
21. Whiteford JR, Behrends V, Kirby H, Kusche-Gulberg M, Maramtsu T, et al. ((2007)) Syndecans promote integrin mediated adhesion of mesenchymal cells in two distinct pathways. Exp Cell Res 313:: 3902--3013.
22. Klass CM, Couchman JR, Woods A, ((2000)) Control of extracellular matrix assembly by syndecan-2 proteoglycan. J Cell Sci 113:: 493--506.
23. Galante LL, Schwarzbauer JE, ((2007)) Requirements for sulfate transport and the diastrophic dysplasia sulfate transporter in fibronectin matrix assembly. JCB 179:: 999--1009.
24. Chen L, Klass C, Woods A, ((2004)) Syndecan-2 regulates transforming growth factor-beta signaling. J Biol Chem 279:: 15715--15718.
25. Cevikbas F, Schaefer L, Uhlig P, Robenek H, Theilmeier G, et al. ((2008)) Unilateral nephrectomy leads to up-regulation of syndecan-2- and TGF-beta-mediated glomerulosclerosis in syndecan-4 deficient male mice. Matrix Biol 27:: 42--52.
26. Choi S, Kim Y, Park H, Han IO, Chung E, et al. ((2009)) Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. Biochem Biophys Res Commun 384:: 231--235.
27. Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, et al. ((2010)) RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 and alpha5-beta1 integrin co-signaling. J Biol Chem 285:: 40212--40229.
28. Martin JL, Jambazov S, ((2006)) Insulin-like growth factor binding protein-3 in extracellular matrix stimulates adhesion of breast epithelial cells and activation of p44/42 mitogen-activated protein kinase. Endocrinol 147:: 4400--4409.
29. Scheper GC, Morrice NA, Kleijn M, Proud CG, ((2001)) The mitogen-activated protein kinase signal-integrating kinase Mknk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 21:: 743--754.
30. Knauf U, Tschopp C, Gram H, ((2001)) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 21:: 5500--5511.
31. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R, ((2004)) Mknk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24:: 6539--6549.
32. Ryu HY, Lee J, Yang S, Park H, Choi S, et al. ((2009)) Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem 18:: 35692--35701.
33. Huang CC, Chuang JH, Chou MH, Wu CL, Chen CM, et al. ((2005)) Matrilysin MMP-7 is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod Pathol 18:: 941--950.
34. Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, et al. ((2010)) production and activation of matrix metalloproteinase 7 matrilysin 1 in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med 134:: 1136--1142.
35. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, et al. ((2007)) A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 282:: 28164--28174.
36. Essner JJ, Chen E, Ekker SC, ((2006)) Syndecan-2. Int J Biochem Cell Biol 38:: 152--156.
37. Park H, Kim Y, Lim Y, Han I, Oh ES, ((2002)) Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 277:: 29730--29736.
38. Villena J, Berndt C, Granés F, Reina M, Vilaró S, ((2003)) Syndecan-2 expression enhances adhesion and proliferation of stably transfected Swiss 3T3 cells. Cell Biol Int 27:: 1005--1010.
39. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS, ((2001)) Syndecan-1 CD138 immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:: 1052--1058.
40. Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, ((2005)) Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 167:: 1699--1711.
41. Kliment CR, Englert JM, Gochuico BR, Yu G, Kaminski N, ((2009)) Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem 284:: 3537--3545.
42. Frangogiannis NG, ((2010)) Syndecan-1: a critical mediator in cardiac fibrosis. Hypertension 55:: 233--235.
43. Jiang D, Liang J, Campanella GS, Guo R, Yu S, et al. ((2010)) Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J Clin Invest 120:: 2049--2057.
44. Sadikot RT, Christman JW, Blackwell TS, ((2004)) Molecular targets for modulating lung inflammation and injury. 5:: 581--588.